Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gains from Investment Securities (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Gains from Investment Securities data on record, last reported at $35.7 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to $35.7 million; the TTM value through Dec 2025 reached $35.7 million, up 396655.56%, while the annual FY2025 figure was $35.7 million, 114.47% up from the prior year.
  • Gains from Investment Securities reached $35.7 million in Q4 2025 per LCTX's latest filing, up from $29000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $35.7 million in Q4 2025 and bottomed at -$4000.0 in Q4 2023.
  • Average Gains from Investment Securities over 5 years is $6.6 million, with a median of $33000.0 recorded in 2023.
  • Peak YoY movement for Gains from Investment Securities: tumbled 100.03% in 2023, then soared 825.0% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $5.2 million in 2021, then skyrocketed by 134.55% to $12.2 million in 2022, then crashed by 100.03% to -$4000.0 in 2023, then changed by 0.0% to -$4000.0 in 2024, then skyrocketed by 892175.0% to $35.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $35.7 million in Q4 2025, $29000.0 in Q3 2025, and -$4000.0 in Q3 2024.